Radical surgery best option for most ovarian cancer patients with cancer in diaphragmOctober 13, 2005ROCHESTER, Minn. - In a retrospective study looking back at a decade of surgeries, Mayo Clinic Cancer Center researchers have determined that surgery to remove metastatic disease from the diaphragm, in conjunction with other procedures to remove the primary diseased tissue in ovarian cancer patients, significantly increases survival rates. Study results were published in Gynecologic Oncology online. "Surgeons have long believed that removing as much diseased tissue as possible is important for survival of cancer patients," said William Cliby, M.D., associate professor of obstetrics and gynecology at Mayo Clinic. "The choice of many surgeons to not resect diaphragm disease in ovarian cancer patients seemed counterintuitive, but it was based on the feeling that it might not improve survival. We sought to address this issue." Dr. Cliby's team cited lack of evidence of survival benefit, concerns over safety (related to complexity and length of the surgery) and lack of surgeon experience as justifications often given for not proceeding with diaphragmatic surgery in advanced ovarian cancer patients. This study provided strong evidence of survival benefit. The five-year survival rates for patients with diaphragm disease who had optimal residual disease (less than 1 cm) was 55 percent for those undergoing diaphragm surgery versus 28 percent for those who did not. The study group included 244 consecutive patients with primary ovarian cancer who were operated on at Mayo Clinic from 1994 through 1998 and from Aug. 1, 2002, through Aug. 31, 2004. Dr. Cliby and his colleagues found that at Mayo Clinic, the rate of diaphragm procedures for affected patients increased from 22.5 percent in the first period compared to 40 percent in the more recent period. They attribute this to increased surgeon experience, increased recognition of the importance of maximal effort for tumor resection and the cooperative working relationships with other surgical specialties at Mayo Clinic that provide the opportunity to train interdepartmentally and improve surgical techniques. "We hope to continue improving upon our ability to remove cancer disease from all affected areas," said Dr. Cliby. "With each operation, our surgeons become better equipped to handle the most difficult of surgeries, providing hope for more patients." The researchers conclude that while health issues in some patients will complicate the success of surgery in general, and prevent the option of radical surgery, surgeons should work to increase the rate of tumor reduction, including diaphragm surgery, in appropriate cases. In addition to Dr. Cliby, the research team included Giovanni Aletti, M.D.; Sean Dowdy, M.D.; and Karl Podratz, M.D., Ph.D. Mayo Clinic |
|||||||||||||||||||||
| Related Ovarian Cancer Current Events and Ovarian Cancer News Articles FDA approved leukemia drugs shows promise in ovarian cancer cells The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. American Dietetic Association Releases Updated Position Paper Promoting and Supporting Breastfeeding The American Dietetic Association has released an updated position paper on breastfeeding that details health benefits for both infants and mothers and encourages promotion of breastfeeding whenever possible. Metals could forge new cancer drug Drugs made using unusual metals could form an effective treatment against colon and ovarian cancer, including cancerous cells that have developed immunity to other drugs, according to research at the University of Warwick and the University of Leeds. Breast cancer patients with high risk gene diagnosed 6 years earlier than generation before Women with a deleterious gene mutation are diagnosed with breast cancer six years earlier than relatives of the previous generation who also had the disease and/or ovarian cancer, according to new research from The University of Texas M. D. Anderson Cancer Center. Cancer Predisposition From Gene Variant Shows Strong Gender Bias Cancer predisposition resulting from the presence of a specific gene variant shows a strong gender bias, researchers at the University of Cincinnati (UC) have demonstrated. Medications Effective in Reducing Risks for Breast Cancer Can Also Cause Serious Side Effects Three drugs that reduce a woman's chance of getting breast cancer also have been shown to cause adverse effects, according to a new report from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health & Human Services. Scientists from University of Hawaii at Manoa find genetic marker A new genetic marker associated with ovarian cancer risk was recently discovered by an international research group, led by scientists from the Cancer Research Genetic Epidemiology Unit in the United Kingdom. New treatment in sight for ovarian cancer In the future, women with metastatic ovarian cancer could be treated with a radioactive substance that can seek and destroy tumour cells. Young early stage ovarian cancer patients can preserve fertility A new study finds that young women with early-stage ovarian cancer can preserve future fertility by keeping at least one ovary or the uterus without increasing the risk of dying from the disease. Estrogen-Dependent Switch Tempers Killing Activity of Immune Cells The sex hormone estrogen tempers the killing activity of a specific group of immune cells, the cytotoxic T cells (CTLs), which are known to attack tumor cells and cells infected by viruses. More Ovarian Cancer Current Events and Ovarian Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||